Does the media prefer MDGL or VKTX?

In the previous week, Viking Therapeutics had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 30 mentions for Viking Therapeutics and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.12 beat Viking Therapeutics' score of 0.65 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LLY or VKTX?

In the previous week, Eli Lilly and Company had 79 more articles in the media than Viking Therapeutics. MarketBeat recorded 109 mentions for Eli Lilly and Company and 30 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.88 beat Viking Therapeutics' score of 0.65 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 66 Very Positive mention(s) 18 Positive mention(s) 19 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Viking Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VKTX or PFE?

In the previous week, Pfizer had 37 more articles in the media than Viking Therapeutics. MarketBeat recorded 67 mentions for Pfizer and 30 mentions for Viking Therapeutics. Pfizer's average media sentiment score of 0.81 beat Viking Therapeutics' score of 0.65 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 39 Very Positive mention(s) 9 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to BBIO or VKTX?

In the previous week, Viking Therapeutics had 18 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Viking Therapeutics and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 1.45 beat Viking Therapeutics' score of 0.65 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VKTX or ASND?

In the previous week, Viking Therapeutics had 15 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 30 mentions for Viking Therapeutics and 15 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.54 beat Viking Therapeutics' score of 0.65 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 12 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Viking Therapeutics (VKTX) Competitors

$31.70 -1.41 (-4.26%)

As of 10:11 AM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, BBIO, and ASND

Should you buy Viking Therapeutics stock or one of its competitors? MarketBeat compares Viking Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), BridgeBio Pharma (BBIO), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Madrigal Pharmaceuticals currently has a consensus price target of $688.20, indicating a potential upside of 46.75%. Viking Therapeutics has a consensus price target of $97.88, indicating a potential upside of 208.77%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.28	-$288.28M	-$12.80	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Viking Therapeutics had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 30 mentions for Viking Therapeutics and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.12 beat Viking Therapeutics' score of 0.65 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Madrigal Pharmaceuticals' return on equity of -50.15% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
Viking Therapeutics	N/A	-86.54%	-77.75%

Madrigal Pharmaceuticals has a beta of -1.05, indicating that its stock price is 205% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Summary

Madrigal Pharmaceuticals beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Eli Lilly and Company presently has a consensus target price of $1,283.64, suggesting a potential upside of 14.20%. Viking Therapeutics has a consensus target price of $97.88, suggesting a potential upside of 208.77%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	2 Strong Buy rating(s)	2.87
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Eli Lilly and Company had 79 more articles in the media than Viking Therapeutics. MarketBeat recorded 109 mentions for Eli Lilly and Company and 30 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.88 beat Viking Therapeutics' score of 0.65 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	66 Very Positive mention(s)	18 Positive mention(s)	19 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Viking Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

Eli Lilly and Company has a net margin of 34.98% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 105.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Viking Therapeutics	N/A	-86.54%	-77.75%

Eli Lilly and Company has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	16.24	$20.64B	$28.15	39.93
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Eli Lilly and Company beats Viking Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Viking Therapeutics (NASDAQ:VKTX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pfizer has a net margin of 11.83% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.44% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-86.54%	-77.75%
Pfizer	11.83%	19.44%	8.41%

Viking Therapeutics currently has a consensus price target of $97.88, indicating a potential upside of 208.77%. Pfizer has a consensus price target of $28.50, indicating a potential upside of 14.81%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Viking Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Pfizer	$63.31B	2.23	$7.77B	$1.31	18.95

In the previous week, Pfizer had 37 more articles in the media than Viking Therapeutics. MarketBeat recorded 67 mentions for Pfizer and 30 mentions for Viking Therapeutics. Pfizer's average media sentiment score of 0.81 beat Viking Therapeutics' score of 0.65 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	39 Very Positive mention(s)	9 Positive mention(s)	12 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Pfizer beats Viking Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Viking Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$579.96M	26.89	-$724.93M	-$3.74	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Viking Therapeutics had 18 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Viking Therapeutics and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 1.45 beat Viking Therapeutics' score of 0.65 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Viking Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Viking Therapeutics	N/A	-86.54%	-77.75%

BridgeBio Pharma currently has a consensus price target of $95.21, suggesting a potential upside of 19.36%. Viking Therapeutics has a consensus price target of $97.88, suggesting a potential upside of 208.77%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

BridgeBio Pharma has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

BridgeBio Pharma beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Viking Therapeutics (NASDAQ:VKTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Viking Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Ascendis Pharma A/S has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Ascendis Pharma A/S	$814.57M	18.69	-$258M	$8.67	28.16

76.0% of Viking Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Viking Therapeutics had 15 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 30 mentions for Viking Therapeutics and 15 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.54 beat Viking Therapeutics' score of 0.65 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Viking Therapeutics presently has a consensus target price of $97.88, suggesting a potential upside of 208.77%. Ascendis Pharma A/S has a consensus target price of $296.72, suggesting a potential upside of 21.55%. Given Viking Therapeutics' higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

Ascendis Pharma A/S has a net margin of 57.87% compared to Viking Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-86.54%	-77.75%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Summary

Ascendis Pharma A/S beats Viking Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.72B	$3.66B	$6.88B	$12.34B
Dividend Yield	N/A	2.13%	2.65%	10.11%
P/E Ratio	-6.88	22.99	27.47	23.70
Price / Sales	N/A	212.94	492.21	78.82
Price / Cash	N/A	165.25	51.74	58.30
Price / Book	5.61	7.90	9.98	5.84
Net Income	-$359.64M	$23.81M	$3.61B	$336.54M
7 Day Performance	-8.89%	-0.95%	-0.12%	0.29%
1 Month Performance	-18.74%	-7.38%	-3.82%	-4.99%
1 Year Performance	-2.68%	39.02%	22.83%	17.71%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	3.6259 of 5 stars	$31.70 -4.3%	$97.88 +208.8%	-1.8%	$3.72B	N/A	N/A	20	Trending News Earnings Report Analyst Forecast Insider Trade
MDGL Madrigal Pharmaceuticals	4.2183 of 5 stars	$537.58 -1.7%	$687.93 +28.0%	+70.1%	$12.61B	$958.40M	N/A	90	Trending News Earnings Report Analyst Forecast Short Interest Decrease
LLY Eli Lilly and Company	4.0026 of 5 stars	$1,163.70 -1.0%	$1,283.64 +10.3%	+52.1%	$1.11T	$72.25B	41.34	50,000	Trending News Upcoming Earnings Analyst Revision Gap Down
PFE Pfizer	4.2177 of 5 stars	$24.85 -0.4%	$28.50 +14.7%	+4.6%	$142.14B	$62.58B	18.97	75,000	Trending News Upcoming Earnings Analyst Revision
BBIO BridgeBio Pharma	3.3433 of 5 stars	$82.66 +0.3%	$95.21 +15.2%	+80.1%	$16.15B	$502.08M	N/A	400	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BBIO, and ASND

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Summary

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BBIO, and ASND

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Do insiders & institutionals believe in MDGL or VKTX?

Do analysts recommend MDGL or VKTX?

Which has better earnings & valuation, MDGL or VKTX?

Does the media prefer MDGL or VKTX?

Is MDGL or VKTX more profitable?

Which has more volatility & risk, MDGL or VKTX?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Do analysts rate LLY or VKTX?

Does the media prefer LLY or VKTX?

Is LLY or VKTX more profitable?

Which has more volatility & risk, LLY or VKTX?

Which has higher valuation & earnings, LLY or VKTX?

Do institutionals & insiders have more ownership in LLY or VKTX?

Summary

How does Viking Therapeutics compare to Pfizer?

Do insiders and institutionals believe in VKTX or PFE?

Is VKTX or PFE more profitable?

Do analysts prefer VKTX or PFE?

Which has more volatility & risk, VKTX or PFE?

Which has stronger valuation and earnings, VKTX or PFE?

Does the media favor VKTX or PFE?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Which has preferable valuation & earnings, BBIO or VKTX?

Does the media refer more to BBIO or VKTX?

Do insiders & institutionals hold more shares of BBIO or VKTX?

Is BBIO or VKTX more profitable?

Do analysts rate BBIO or VKTX?

Which has more volatility & risk, BBIO or VKTX?

Summary

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Which has more volatility and risk, VKTX or ASND?

Which has higher valuation & earnings, VKTX or ASND?

Do insiders and institutionals have more ownership in VKTX or ASND?

Does the media favor VKTX or ASND?

Do analysts recommend VKTX or ASND?

Is VKTX or ASND more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools